MECHANO-THERAPEUTICS
A Novel Therapeutic Platform for Human Diseases
Our Team is Positioned to be the Leader in the Discovery and Development of Mechano-Therapeutics, First-in-Class Drugs Designed To Inhibit Novel Targets Driving Pathologic Cell Behavior in Cancer and Fibrosis
Our Mission
Leveraging Decades of World-leading Expertise in Mechanobiology and a Unique Discovery Platform, Zenon is Dedicated to the Discovery and Development of Innovative Mechano-Therapeutics, First in Class Drugs to Treat Unmet Clinical Needs or Improved Outcomes for Patients
Our Programs
Zenon’s Drug Discovery Programs target Cellular Mechano-Sensors in Cancer and Fibrosis. These Novel Disease Intervention Points were Identified by Zenon’s Founder and CEO, David Lagares, at Harvard Medical School
Meet Our Team
World-leading Expertise in Mechanobiology